argenx SE - American Depositary Shares (NQ:ARGX)

897.85 +6.09 (+0.68%)

Delayed Quote Updated: 4:00 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX

October 27, 2026

From Pomerantz LLP

Via GlobeNewswire

argenx: 3 Key Takeaways for Long-Term Investors ↗

October 23, 2026

Pipeline expansion into new indications could sustain growth long after VYVGART matures, a rare diversification for a single-drug biotech.

Via The Motley Fool

Topics Earnings

argenx (ARGX) Q3 2026 Earnings Call Transcript ↗

October 23, 2026

VYVGART revenue surged 54% year-over-year amid strategic Forte Biosciences acquisition.

Via The Motley Fool

Topics Earnings

ARGENX SE - ADR (NASDAQ:ARGX) Meets Minervini Trend Template and High Growth Momentum ↗

September 17, 2026

Via Chartmill

What argenex (ARGX) Said on Its Q3 Earnings Call ↗

October 22, 2026

argenex (NASDAQ:ARGX) reported third-quarter 2026 product net sales of $1.7 billion, up 54% from a year earlier and 13% sequentially, as patient growth in generalized myasthenia gravis, or MG, and...

Via MarketBeat

Topics Earnings Intellectual Property

argenx Reports Third Quarter 2026 Financial Results and Provides Business Update

October 22, 2026

From argenx SE

Via GlobeNewswire

argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026

October 19, 2026

From argenx SE

Via GlobeNewswire

argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026

October 15, 2026

From argenx SE

Via GlobeNewswire

ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law

October 12, 2026

From Schall, Brown & Schwartz LLP

Via Business Wire

Thursday's pre-market session: top gainers and losers ↗

October 08, 2026

Via Chartmill

argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease

October 08, 2026

From argenx SE

Via GlobeNewswire

argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease

October 08, 2026

From argenx SE

Via GlobeNewswire

10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now? ↗

October 05, 2026

This biotech stock could soar 30% or more over the next 12 months if some analysts are right.

Via The Motley Fool

argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline

September 29, 2026

From argenx SE

Via GlobeNewswire

Here's Exactly Why Wall Street Thinks Argenx Stock Could Soar 23% Over the Next 12 Months ↗

September 26, 2026

There are good reasons behind analyst's bullish views of this biotech stock.

Via The Motley Fool

2 Wall Street Analysts Think Argenx Can Soar More Than 40%. Here's Why They're Right. ↗

September 20, 2026

It's easy to be bullish about Argenx.

Via The Motley Fool

argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors

September 17, 2026

From argenx SE

Via GlobeNewswire

Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today ↗

September 04, 2026

argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 13.58% on an annualized basis producing an average annual return of 24.86%. Currently, argenx has a market capitalization of...

Via Benzinga

Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated? ↗

September 02, 2026

This biotech innovator could be in only the early chapters of its success story.

Via The Motley Fool

argenx to Present at Upcoming Investor Conferences

September 01, 2026

From argenx SE

Via GlobeNewswire

argenx Completes Acquisition of Forte Biosciences, Inc.

August 27, 2026

From argenx SE

Via GlobeNewswire

Argenx Just Landed Another Phase 3 Win -- and Wall Street May Be Missing the Bigger Story ↗

August 26, 2026

This biotech leader continues to rack up clinical successes.

Via The Motley Fool

Snowflake To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

August 18, 2026

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC...

Via Benzinga

These Analysts Boost Their Forecasts On Argenx ↗

August 18, 2026

Argenx SE (NASDAQ:ARGX) reports positive Phase 3 results for VYVGART Hytrulo in autoimmune myositis. Analysts raise price targets on ARGX stock.

Via Benzinga

There are notable gap-ups and gap-downs in today's session. ↗

August 17, 2026

Via Chartmill

argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing ↗

August 17, 2026

argenx (NASDAQ:ARGX) reported positive top-line results from its Phase III ALKIVIA trial of VYVGART Hytrulo in autoimmune myositis, meeting its primary endpoint in a combined population of patients...

Via MarketBeat

Topics Intellectual Property

$100 Invested In argenx 5 Years Ago Would Be Worth This Much Today ↗

August 17, 2026

argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 13.49% on an annualized basis producing an average annual return of 25.33%. Currently, argenx has a market capitalization of...

Via Benzinga

argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

August 17, 2026

From argenx SE

Via GlobeNewswire

Here’s How Much You Would Have Made Owning argenx Stock In The Last 5 Years ↗

August 10, 2026

argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 11.1% on an annualized basis producing an average annual return of 22.73%. Currently, argenx has a market capitalization of...

Via Benzinga

argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

August 06, 2026

From argenx SE

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.